A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Acrivon Therapeutics
Artios Pharma Ltd
Merck Sharp & Dohme LLC
Incyte Corporation
Yonsei University
Esperas Pharma Inc.
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)